EPIPEN JR. Drug Patent Profile

Which patents cover Epipen Jr., and when can generic versions of Epipen Jr. launch?

Epipen Jr. is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in EPIPEN JR. is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epipen Jr.

A generic version of EPIPEN JR. was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for EPIPEN JR.

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for EPIPEN JR.

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIPEN JR.	Injection (Auto- injector)	epinephrine	0.15 mg/0.3 mL and 0.3 mg/0.3 mL	019430	1	2009-07-20

US Patents and Regulatory Information for EPIPEN JR.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	AB	RX	Yes	Yes

International Patents for EPIPEN JR.

See the table below for patents covering EPIPEN JR. around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	200613027	Automatic injector
Denmark	2204201
European Patent Office	1786491
Slovenia	2204201

Supplementary Protection Certificates for EPIPEN JR.

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823

Investment Scenario, Market Dynamics, and Financial Trajectory for Epipen Jr.

Last updated: February 3, 2026

Summary

EpiPen Jr., a pre-filled auto-injector delivering epinephrine to treat severe allergic reactions (anaphylaxis) in children, remains pivotal in allergy management. This report evaluates its current market position, growth potential, competitive landscape, regulatory considerations, and financial trajectory. Despite challenges like pricing controversies and patent expiries, EpiPen Jr. continues to show resilience driven by increasing allergy prevalence and heightened awareness. Strategic insights indicate steady revenue streams with potential for growth amid evolving healthcare policies and innovation pipelines.

---

What Is the Current Market Scope of EpiPen Jr.?

Market Size and Penetration

Metric	Data	Source	Notes
Global allergy treatment market	USD 19.2 billion (2022)	Grand View Research[1]	Growing at CAGR of 8.2% (2023–2030)
EpiPen sales (all formulations)	~$1.2 billion (2022)	IQVIA	Focused on North America, key markets
Children-specific effective market	Estimated USD 300 million	Industry estimates	Subset of total allergy market

Patient Demographics

Age Group	Population (Millions)	Increase (2014–2022)	Source
Children (0-14)	600	+4%	UN Population Data[2]
Allergic children (estimated)	10–12% of children	60–72 million	AAAAI[3]

Market Drivers

• Rising allergy prevalence, particularly food and insect allergies.
• Increased awareness and diagnosis.
• Regulatory mandates for emergency allergy treatment.

---

How Do Market Dynamics Influence EpiPen Jr.?

Competitive Landscape

Competitors	Product Name	Features	Market Share	Strengths	Weaknesses
Mylan/EpiPen	EpiPen (adult and pediatric)	Auto-injector, pre-filled	~75% in North America	Established brand	Price sensitivities, patent expiries
Teva	Auvi-Q	Auto-injector with voice prompts	~10%	User-friendly	Limited distribution
Kaléo	Adrenaclick	Injectable pen	~8%	Lower cost	Limited availability
generics	Various	Auto-injectors	7%	Price competitiveness	Brand recognition

Regulatory Trends

• FDA approvals: Focused on safety and ease of use enhancements.
• Legislation: School and public access mandates elevate demand.
• Patent expiries: EpiPen patents expired in 2017, increasing generic competition.

Pricing and Reimbursement

Aspect	Details
Retail Price (EpiPen Jr.)	Approx. USD 300–350 per two-pack (brand), reduced after rebates	Pharmaceutical Pricing Data
Insurance Coverage	Widely reimbursable in the US; Medicaid, private insurers cover most costs
Rebate strategies	Dominant in maintaining sales volume amidst pricing scrutiny

Supply Chain Dynamics

• Dependence on active pharmaceutical ingredients (APIs) from limited suppliers.
• Manufacturing capacity expansions, e.g., Mylan's plant investment in 2019.

---

What Are the Key Financial Trajectories for EpiPen Jr.?

Revenue Projection Scenarios (2023–2028)

Scenario	Assumptions	Revenue (USD Millions)	Compound Annual Growth Rate (CAGR)
Conservative	Market saturation, patent challenges persist	USD 800–900	2-4%
Moderate	Increasing allergy awareness, expanding indications	USD 1,100–1,300	8-10%
Optimistic	Introduction of new formulations, emergency market expansion	USD 1,400–1,600	12-15%

Factors Affecting Revenue

• Patent and Exclusivity: Major patent loss in 2017 led to increased generic competition. Future patent filings or exclusivities (e.g., new formulations) can influence market share.
• Pricing Strategies: Rebate and access negotiations determine net margins.
• Market Penetration: Growth in emerging markets and expansion into new indications (e.g., device upgrades).

Cost Structure Insights

Expense Item	Approximate Percentage of Revenue	Notes
R&D	8–10%	Ongoing innovations, new delivery systems
Manufacturing	15–20%	Raw materials, capacity expansion
Marketing & Sales	20–25%	Education campaigns, payer negotiations
Distribution & Logistics	10–12%	Global supply chain

---

How Do Regulatory and Policy Developments Impact EpiPen Jr.?

Policy/Regulation	Impact	Status	Source
US FDA Guidance	Facilitates device approval, safety standards	Active	FDA[4]
Affordable Care Act	Improves insurance coverage	Enforced	US Government[5]
State legislation for public access	Increases distribution channels	Varies	State Health Agencies
Price transparency laws	Pressures pricing models	Emerging	CMS (Centers for Medicare & Medicaid Services)

---

Comparison with Alternatives and Future Outlook

Aspect	EpiPen Jr.	Auvi-Q	Adrenaclick	Future Innovations
Ease of Use	High	Very high (voice prompts)	Moderate	Digital and connected devices
Price	USD 300–350 (retail)	USD 370–400	USD 100–200	Potential lower-cost options
Market Position	Dominant	Niche	Niche	Emerging products

Emerging Trends

• Digital integration: Smartphone-compatible auto-injectors.
• Smart features: Data logging for adherence.
• Alternate delivery systems: Patch-based injectors, nasal sprays.

---

Key Challenges and Opportunities

Challenges	Opportunities
Patent expiries leading to generic competition	Product differentiation and innovation
Pricing controversies and public perception	Value-based pricing, enhanced patient education
Supply chain vulnerabilities	Diversification of suppliers, manufacturing capacity
Regulatory hurdles	Streamlined approval pathways for new devices

---

Conclusion: Financial and Strategic Outlook

Despite patent expiries and competitive pressures, EpiPen Jr. maintains a resilient market presence due to increasing allergy incidence, regulatory mandates, and brand recognition. Revenue projections suggest steady growth, particularly with innovation and market expansion. Companies leveraging digital health innovations and strategic pricing can capitalize on future opportunities, bolstering long-term financial trajectory.

---

Key Takeaways

• Market Growth: Driven by rising allergy prevalence, reached approximately USD 1.2 billion in sales (2022).
• Revenue Stability: Steady growth expected in a CAGR of 2–10% over the next five years depending on innovation and market dynamics.
• Competitive Landscape: Dominated by EpiPen, facing increasing generic competition; innovation remains critical.
• Regulatory Environment: Favorable with ongoing approval processes and public mandates for emergency treatment access.
• Strategic Focus: Emphasize product innovation, pricing strategies, and global expansion to sustain growth.

---

FAQs

1. What is the primary driver of EpiPen Jr.'s market growth?
   The increasing prevalence of allergies, especially among children, alongside regulatory mandates requiring access to emergency treatment facilitates sustained demand.

2. How has patent expiry affected EpiPen Jr. sales?
   Patent expiries in 2017 led to increased generic competition, reducing revenue margins but maintaining overall market share due to brand recognition and insurance reimbursement.

3. What are the key competitors to EpiPen Jr.?
   Auvi-Q and Adrenaclick are notable alternatives, with new digital and voice-assisted devices appearing, though none currently surpass EpiPen’s market dominance.

4. What regulatory trends could influence EpiPen Jr.’s future?
   Regulatory pathways favor innovation, including approvals for connected devices; however, price transparency laws may pressure reimbursement strategies.

5. What innovation opportunities exist for future growth?
   Digital health integration, alternative delivery systems, and expanding indications or markets in emerging economies represent significant growth opportunities.

---

Citations

[1] Grand View Research. Global allergy treatment market size, Share & Trends Analysis, 2023–2030.

[2] United Nations. World Population Prospects, 2022.

[3] AAAAI. Allergy Demographics, 2021.

[4] FDA. Device Approval & Guidance, 2022.

[5] US Government. Affordable Care Act Summary, 2023.